7.59
Cervomed Inc Borsa (CRVO) Ultime notizie
Reviewing CervoMed (CRVO) and Its Peers - Defense World
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CervoMed Releases New Business and Financial Information - TipRanks
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Chardan Capital Raises Earnings Estimates for CervoMed - Defense World
Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World
Brokers Set Expectations for CervoMed Q2 Earnings - Defense World
Insider Buying: William Elder Acquires Additional Shares of Cerv - GuruFocus
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from D. Boral Capital - Defense World
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - MSN
CervoMed’s CFO Makes Bold Move with New Stock Purchase! - TipRanks
CervoMed First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Chardan keeps CervoMed stock Buy rating, $15 target post-results - Investing.com Australia
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | - GuruFocus
Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating - marketscreener.com
CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | CRVO Stock News - GuruFocus
CervoMed Announces $50M Sales Agreement with Leerink - TipRanks
Chardan Capital Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed Inc. Reports Q1 2025 Financial Results - TipRanks
Chardan keeps CervoMed stock Buy rating, $15 target post-results By Investing.com - Investing.com South Africa
CervoMed Inc (CRVO) Q1 2025 Earnings: Revenue Beats Estimates at $1.9M, Net Loss Reported - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stoc - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target | CRVO Stock News - GuruFocus
Cervomed Co Enters Sales Agreement With Leerink Partners LLC - marketscreener.com
CervoMed (CRVO) Financial Position and Funding Outlook | CRVO St - GuruFocus
CervoMed (CRVO) Exceeds Q1 Revenue Expectations Amid Promising T - GuruFocus
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SEC Form 10-Q filed by CervoMed Inc. - Quantisnow
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed Inc. Reports Positive Phase 2b Results for Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies and Plans Phase 3 Trial - Nasdaq
CervoMed (CRVO) to Release Earnings on Tuesday - Defense World
CervoMed Announces Executive Appointments and Changes - MSN
Mariner LLC Invests $30,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
JPMorgan Chase & Co. Grows Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
CRVO Shares Experience Surge in Value - knoxdaily.com
Head to Head Comparison: CervoMed (NASDAQ:CRVO) versus Schrödinger (NASDAQ:SDGR) - Defense World
Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World
What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister
CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa
CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia
CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus
CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):